ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BDSX vs XGN // EV/EBITDA & P/E VALUATION

Biodesix Inc. (NASDAQ) VS. Exagen Inc. (NASDAQ) • 15-METRIC TALLY: BDSX 2 — XGN 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDSX VS. XGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BDSX XGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 58.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -9.02% -6.77% -2.25 XGN /fcf-yield <GO>
Operating Margin -31.50% -21.10% -10.40 XGN /operating-margins <GO>
Net Profit Margin -39.90% -30.00% -9.90 XGN /net-margins <GO>
Revenue Growth (YoY) 24.10% 19.70% +4.40 BDSX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.0 58.6 -14.66 XGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.8M $210.8M $50.1M BDSX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BDSX REV XGN REV BDSX GROSS % XGN GROSS % BDSX FCF XGN FCF
FY 2025 $88.5M $66.6M — 58.3% -$23.5M -$14.3M
FY 2024 $71.3M $55.6M — 59.5% -$51.9M -$13.8M
FY 2023 $49.1M $52.5M — — -$22.9M -$14.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDSX // BETA —
XGN // BETA —